Hospital de la Santa Creu i Sant Pau
If you are the contact person for this centre and you wish to make any changes, please contact us.
Neurologist in charge of the “Central Autoimmune Neurology Unit” at the Hospital de la Santa Creu i Sant Pau in Barcelona
Specialist doctor at the Clinical Epidemiology and Public Health Service of the Hospital de Sant Pau in Barcelona and Patient Safety Expert
Director of the Internal Medicine Department and head of the Fibromyalgia and Chronic Fatigue Syndrome Functional Unit at the Hospital Sant Pau in Barcelona
Clinical Head of the Thoracic Surgery Department at the Hospital de la Santa Creu i Sant Pau in Barcelona, co-coordinator of the CASSANDRA lung cancer screening project and director of Integrated Research Projects in Thoracic Oncology at the Spanish Society of Pneumology and Thoracic Surgery (SEPAR)
Director of the Memory Unit of the Neurology Service of the Hospital de la Santa Creu i Sant Pau and director of the Alzheimer's Unit at the Fundació Catalana Sindrome de Down
Director of the Dermatology Department of the Hospital de la Santa Creu i Sant Pau and professor at the Autonomous University of Barcelona
Neurologist in the Neuromuscular Diseases Unit - Autoimmune Neurology - Neuromuscular Lab
Hospital de la Santa Creu i Sant Pau & Institut de Recerca Biomèdica Sant Pau, Barcelona
Specialist in Immunology at the Hospital de Sant Pau in Barcelona and secretary of the Spanish Society of Immunology
Clinical Head of the Headache and Neuralgia Unit at the Neurology Department of the Hospital de la Santa Creu i Sant Pau in Barcelona
Neurologist at the Memory Unit of the Hospital de la Santa Creu i Sant Pau.
EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.
A CNIC research team has identified a population of skin neutrophils that reinforce the physical protection of the tissue against infection. These immune cells are known for their microbicidal role, and the study published in Nature reveals that they also produce an extracellular matrix that reinforces the physical barrier of the skin.
Less than four months after the European Medicines Agency recommended in July not to grant marketing authorisation for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease, the EMA's Committee for Medicinal Products for Human Use (CHMP) has reassessed the available evidence to conclude that the benefits outweigh the risks.
Rituximab and ocrelizumab are two antibodies with a similar mechanism of action that are used in the treatment of multiple sclerosis. Although the former had not shown benefits in primary progressive multiple sclerosis — which affects between 10% and 15% of patients — the latter is approved for this form of the disease. Now, a study conducted in France with more than 1,000 patients has found no benefits with either treatment, as they did not slow the progression of disability in these individuals. The results are published in the journal Neurology.
An international team of researchers has conducted a meta-analysis of 137 clinical trials involving nearly 90,000 people to assess the migraine efficacy of 17 available drugs. Their conclusions are that four drugs in the triptan group are more effective and cheaper than newer drugs such as gepants or lasmiditan, and that the efficacy of the latter is comparable to that of paracetamol and most anti-inflammatory drugs. The results are published in The BMJ.
Vision loss and having high cholesterol - the so-called ‘bad’ cholesterol - are risk factors for developing dementia, according to a meta-analysis published in The Lancet. Eliminating these risk factors could reduce dementia cases by 2% and 7% respectively, the study says. Both factors are in addition to 12 others previously mentioned in a 2020 report such as less education, physical inactivity, hearing loss, excessive alcohol consumption, obesity or poor social contact, among others. According to the research, almost half of all dementia cases could be prevented or delayed if these risk factors were controlled.
A family of more than 1,000 members with origins in Colombia has a mutation called "paisa" that leads to the development of Alzheimer's disease. In 2019, an added mutation in the apoE gene called "Christchurch" was described as conferring strong protection to an individual carrying two copies of it. Now, a study has found that 27 family members carry a single copy and that it is also associated with some degree of protection. According to the authors, who publish their findings in the journal NEJM, the discovery could be used to develop new treatments for the disease.
The number of patients who suffered harm associated with medical procedures, treatments and contact with healthcare systems increased by 59% worldwide between 1990 and 2019, according to a study published in the journal BMJ Quality & Safety. This is higher than the population growth of 45 % over the same time period. Older people suffer the most adverse effects, with the main increase occurring in those aged 65-69 years.
Researchers have found specific antibodies in the blood of patients years before they showed symptoms of multiple sclerosis. This group of antibodies was present in 10% of the 250 people who later developed the disease, and were part of a sample of over 10 million US military personnel. The finding could have potential for early detection of multiple sclerosis, says the research team in a paper published in Nature Medicine.
An antibody therapy is able to restore the immune system of elderly mice to a more youthful state. The method, published in the journal Nature, rebalances blood cell production and reduces age-related immune decline. Preclinical and clinical studies are needed to determine whether this approach could be feasible in humans.